ImmunoGen, Inc. Form 8-K
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d)
OF
THE SECURITIES EXCHANGE ACT OF 1934
Date
of
Report (Date of earliest event reported): March 27, 2006
ImmunoGen,
Inc.
(Exact
name of registrant as specified in its charter)
| |
Massachusetts
|
0-17999
|
04-2726691
|
|
| |
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
|
128
Sidney Street, Cambridge, MA 02139
(Address
of principal executive offices) (Zip Code)
Registrant's
telephone number, including area code: (617) 995-2500
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see
General
Instruction A.2. below):
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
ITEM
1.01 - AMENDMENT OF A MATERIAL DEFINITIVE AGREEMENT
On
March
27, 2006, ImmunoGen, Inc. (NASDAQ: IMGN) and Millennium Pharmaceuticals, Inc.
(NASDAQ: MLNM) agreed to amend the Access, Option and License Agreement (the
Agreement) executed by the parties on March 30, 2001. The amendment extends
the
Access Term, as defined in the Agreement, for an additional year, which ends
March 30, 2007. In consideration for this extension, Millennium will pay to
ImmunoGen an extension fee equal to two hundred and fifty thousand dollars
($250,000).
A
copy of
the press release is attached to this current report on Form 8-K as Exhibit
99.1.
ITEM
9.01. FINANCIAL STATEMENTS AND EXHIBITS
|
Exhibit
No.
|
|
Exhibit
|
| |
|
|
|
99.1
|
|
Press
Release of ImmunoGen, Inc. dated March 30,
2006
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
|
|
| |
ImmunoGen,
Inc. |
|
|
|
| Date: March
30, 2006 |
By: |
/s/ Karleen
M. Oberton |
| |
|
| |
Senior
Corporate Controller
(Principal Accounting
Officer)
|